Irinotecan- vs oxaliplatin-based regimens for neoadjuvant chemotherapy in colorectal liver metastasis patients: A retrospective study

Table 2 Demographic and clinical characteristics of patients after propensity score matching

Patient demographic	All patients (n = 350)	Irinotecan group (n = 175)	Oxaliplatin group (n = 175)	P value
Age (yr)	56.0 ± 4.2	56.2 ± 9.6	55.7 ± 10.1	0.632
Sex ration (male:female)	230:120	121:54	109:66	0.177
Primary T stage				0.433
T1-2	47	21	26
T3-4	303	154	149
Primary N stage				0.526
N0	104	51	53
N1-2	246	125	121
Primary tumor location				0.756
Colon	205	101	104
Rectum	145	74	71
Primary tumor side				0.745
Right	48	25	23
Left	302	150	152
Timing of liver metastasis				0.077
Synchronous	283	135	148
Metachronous	67	40	27
Tumor number (median)	2 (1-25)	2 (1-25)	2 (1-22)	0.422
Tumor size (mm, mean ± SD)	28.8 ± 18.9	29.2 ± 20.3	28.4 ± 17.5	0.681
Localization of liver metastases				0.493
Unilobar	190	98	92
Bilobar	160	77	83
CEA level (ng/mL)	27.81 ± 64.87	24.26 ± 55.81	31.36 ± 72.81	0.307
CA 19-9 level (IU/mL)	228.71 ± 203.76	212.92 ± 145.70	244.51 ± 266.39	0.894
Extrahepatic metastasis				0.311
No	293	150	143
Yes	57	25	32
RAS mutation				0.912
Wild type	221	111	110
Mutation	129	64	65
Biological agent				0.169
Cetuximab	100	53	47
Bevacizumab	167	88	79
No	83	34	49
Response				0.176
Complete response	1	0	1
Partial response	144	70	74
Stable disease	183	98	85
Progressive disease	22	7	15
Cycles	4 (0-10)	4 (0-10)	4 (0-10)	0.948
Concomitant ablation therapy	66	36	30	0.464
CRS				0.669
0-2	166	81	85
3-5	184	94	90
Simultaneous resection	88	39	49	0.443
Staged resection	262	136	126
Intraoperative blood loss (mL)	222 ± 211	201 ± 181	264 ± 235	0.024
Intraoperative RBC transfusion	15	8	7	0.117
Intraoperative RBC transfusion (U)	2 (1-12)	2 (1-6)	2 (2-6)	0.281
Operation time (min)	198 ± 73	188 ± 73	208 ± 72	0.012
Hepatic resection				0.886
Major resection	90	42	45
Minor resection	260	133	130
Margin status				0.367
Positive	32	17	15
Negative	318	158	160
Clavien-Dindo classification				0.019
I-II	102	43	59
III-V	22	7	15
Adjuvant chemotherapy				0.352
No	132	41	91
Yes	422	160	262

PSM: Propensity score matching; CEA: Carcinoembryonic antigen; CA 19-9: Carbohydrate antigen 19-9; RBC: Red blood cell; CRS: Clinical risk score.